APOB and Parkinson disease: Therefore, low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apoB) have the potential to serve as appropriate biomarkers for comparative investigations of alirocumab and evolocumab in the context of Parkinson’s disease (PD) [212].